Physician profile
Dina Strachan
NPI 1164466967
$11,916.71
in general payments reported to CMS, 2019-2025
32 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $749 · 2021: $962 · 2022: $928 · 2023: $1,607 · 2024: $4,354 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,492 · Travel and Lodging: $2,406 · Education: $187 · Gift: $33.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,491.81 |
| Travel and Lodging | $2,405.63 |
| Education | $186.99 |
| Gift | $33.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,765.51 | 2019-2025 | Rinvoq |
| Galderma Laboratories, L.P. | $2,046.24 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $599.94 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $578.79 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Incyte Corporation | $454.46 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $400.08 | 2019-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $381.16 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $367.71 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $326.29 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $307.87 | 2023-2025 | Mounjaro, Taltz, Ebglyss |
| Leo Pharma INC. | $299.73 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $291.37 | 2019-2025 | |
| Dermavant Sciences, INC. | $233.17 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $224.37 | 2019-2025 | |
| Almirall LLC | $219.25 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $191.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $188.04 | 2022-2024 | Sotyktu |
| Botanix Sb INC | $173.56 | 2025 | Sofdra |
| Amgen INC. | $172.28 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $168.30 | 2020-2023 | Dupixent |
| Genentech, INC. | $146.14 | 2020 | |
| Sanofi-Aventis U.S. LLC | $92.00 | 2024 | |
| Epi Health, LLC | $76.79 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $52.11 | 2020-2021 | |
| Sandoz INC. | $37.26 | 2020-2021 | |
| Journey Medical Corporation | $24.55 | 2022 | |
| Organon LLC | $18.44 | 2025 | Vtama |
| Dermira, INC. | $16.51 | 2021 | |
| Celgene Corporation | $16.40 | 2019 | |
| Merz North America, INC. | $16.00 | 2019 | |
| Allergan, INC. | $15.90 | 2019 | |
| Prugen, INC. Pharmaceuticals | $14.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Strachan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.